You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Details for New Drug Application (NDA): 210833


✉ Email this page to a colleague

« Back to Dashboard


NDA 210833 describes SYMPAZAN, which is a drug marketed by Otter Pharms and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the SYMPAZAN profile page.

The generic ingredient in SYMPAZAN is clobazam. There are ten drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the clobazam profile page.
Summary for 210833
Tradename:SYMPAZAN
Applicant:Otter Pharms
Ingredient:clobazam
Patents:3
Pharmacology for NDA: 210833
Suppliers and Packaging for NDA: 210833
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SYMPAZAN clobazam FILM;ORAL 210833 NDA Aquestive Therapeutics 10094-205 10094-205-60 60 POUCH in 1 PACKAGE (10094-205-60) / 1 FILM in 1 POUCH (10094-205-01)
SYMPAZAN clobazam FILM;ORAL 210833 NDA Aquestive Therapeutics 10094-210 10094-210-60 60 POUCH in 1 PACKAGE (10094-210-60) / 1 FILM in 1 POUCH (10094-210-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:FILM;ORALStrength5MG
Approval Date:Nov 1, 2018TE:RLD:Yes
Patent:⤷  Sign UpPatent Expiration:Jan 31, 2040Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD OF TREATING SEIZURES
Patent:⤷  Sign UpPatent Expiration:Apr 3, 2024Product Flag?YSubstance Flag?Delist Request?
Patent:⤷  Sign UpPatent Expiration:Feb 20, 2024Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 210833

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Otter Pharms SYMPAZAN clobazam FILM;ORAL 210833-003 Nov 1, 2018 ⤷  Sign Up ⤷  Sign Up
Otter Pharms SYMPAZAN clobazam FILM;ORAL 210833-001 Nov 1, 2018 ⤷  Sign Up ⤷  Sign Up
Otter Pharms SYMPAZAN clobazam FILM;ORAL 210833-002 Nov 1, 2018 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.